Inovio Pharmaceuticals (INO) Stock Gets A Boost From Bill Gates

Inovio Pharmaceuticals INO Stock News

Inovio Pharmaceuticals Inc (NASDAQ: INO) is making yet another run for the top in the market this morning, following up on the strong gains that the company saw last week. While the company hasn’t issued any news of its own, the reason for the gains was easy to tie down. Recently comments from Bill Gates seem to be pushing the stock for the top. Here’s what’s happening:

Stop wasting your time. Start finding winning trades in minutes with Trade Ideas!

Bill Gates Sends INO Stock Up

The likely reason for the strong gains that we’re seeing out of Inovio Pharmaceuticals is an article that was published on Benzinga. The article outlined comments by Bill Gates surrounding how quickly we could have a viable vaccine.

In fact, Gates believes that vaccines for COVID-19 could be produced at a mass scale within a year. In fact, in his own words, Gates said:

If everything went perfectly, we’d be in scale manufacturing within a year. It could be as long as two years. It’s very hard to compress these timeframes.

So, what does this have to do with INO stock? Well… everything.

The Bill & Melinda Gates Foundation has been a big backer of INO and its work to develop a vaccine. Of course, the foundation has supported not just Inovio, but six other companies that are working on COVID-19 vaccine candidates.

Considering his opinion that we are pushing toward the mass production of a vaccine, possibly within a year, and the fact that Gates obviously sees value in INO, it only makes sense that the billionaire’s statements would lead to investor excitement.

INO Could Be The First To Mass Produce A Vaccine

While there are plenty of companies out there that are working on vaccines, few actually have anything of value. That’s not the case for Innovio Pharmaceuticals.

In fact, just hours after receiving the genome sequence of COVID-19, Inovio Pharmaceuticals had already created a vaccine candidate. From there, the company has been working hard to push the candidate thrugh the phases, with human studies taking place as we speak.

Considering the fast pace at which INO is developing its vaccine candidate, there is only one other company that is really a contender, and that’s Moderna (MRNA). Nonetheless, the company is well positioned to be one of the first to develop and mass-manufacture a vaccine, and if all goes well, that could be overwhelmingly profitable. So, investors are right to be excited about INO stock.

Stop wasting your time. Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts.

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.